Engitix and GSK Partner to Advance Liver Fibrosis Drug Discovery
London, UK – June 8, 2026 Engitix Ltd., a biotechnology company specializing in extracellular matrix (ECM)-driven drug discovery, has...
Foundayo
Advertisement
Lilly’s Foundayo Outperforms Rivals in Landmark Diabetes Trials
INDIANAPOLIS, USA – June 8, 2026 Eli Lilly and Company has reported compelling new Phase 3 clinical data showing...
Ambrosia’s AMB-702 Shows Superior Weight Loss in Preclinical GLP-1 Studies
BOULDER, Colorado, June 5, 2026 Ambrosia Biosciences has unveiled promising preclinical data for AMB-702, its novel oral small-molecule GLP-1...
Lilly’s Foundayo Shows Strong Weight Loss Across Menopause
INDIANAPOLIS, Indiana, June 7, 2026 Eli Lilly and Company has announced new data demonstrating that Foundayo® (orforglipron), the only...
Lilly Unveils Landmark Phase 3 Data for Foundayo and Retatrutide at ADA 2026
INDIANAPOLIS, May 28, 2026 Eli Lilly and Company has announced a major slate of scientific presentations for the American...
Advertisements
Lilly’s Foundayo Shows Strong Weight Loss in Seniors
Indianapolis, Indiana, USA – May 22, 2026 Eli Lilly and Company announced new clinical analysis from the Phase 3...
Eli Lilly Strengthens GLP-1 Leadership With New Foundayo Trial Results
INDIANAPOLIS, May 12, 2026 Eli Lilly and Company has reported positive results from two major late-phase obesity trials showing...
Lilly Expands Indiana Manufacturing With $4.5B
LEBANON, Indiana, United States – May 6, 2026 Eli Lilly and Company has announced an additional $4.5 billion investment...
Lilly Foundayo Shows Strong Phase 3 Diabetes Results
INDIANAPOLIS, April 16, 2026 Eli Lilly and Company announced positive results from its ACHIEVE-4 Phase 3 clinical trial, demonstrating...
Lilly Launches Foundayo Oral GLP-1 Weight Loss Drug
INDIANAPOLIS, April 9, 2026 Eli Lilly and Company has announced the U.S. launch of Foundayo™ (orforglipron), a first-in-class oral...
Advertisement
